Short Term Rating on Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX) : 2 brokerage houses believe that Progenics Pharmaceuticals (PGNX) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 2 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Progenics Pharmaceuticals (PGNX) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $14 and the lowest price target forecast is $9. The average forecast of all the analysts is $11.5 and the expected standard deviation is $3.54.

For this week, the average consensus of the company shares are rated as a Strong Buy.


Progenics Pharmaceuticals (NASDAQ:PGNX): The stock opened at $5.45 on Tuesday but the bulls could not build on the opening and the stock topped out at $5.49 for the day. The stock traded down to $5.16 during the day, due to lack of any buying support eventually closed down at $5.18 with a loss of -3.54% for the day. The stock had closed at $5.37 on the previous day. The total traded volume was 1,151,118 shares.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *